Qiagen's portfolio of H1N1 surveillance tools include two real-time PCR-based screening tests, a device that detects multiple pathogens in a single run, and protocols for resistance testing. The company's solutions include individual sample-preparation reagents, enzymes, and instrumentation used in testing protocols recommended by international health authorities including the WHO and the CDC. During the last few weeks Qiagen reports that it has entered into supply agreements for consumables and instruments with public health authorities in Europe, Asia, Latin America, and other regions.